L2 Diagnostics

L2 has active research programs in vaccines, small molecule therapeutics, and diagnostics. For more details we invite you to review this selection of peer-reviewed research papers in each of these areas.

image of a doctor vaccinating a patient


Vaccine research at L2 is currently focussed on diseases transmitted by insects (malaria, Zika virus) and ticks (Lyme disease, babesiosis, Powassan virus). We are particularly interested in approaches that target molecules produced by the arthropod vector and are necessary to establish infection. By targeting the vector rather than the pathogen, we may develop a single vaccine that is protective against multiple diseases. This work is conducted in collaboration with the laboratory of Dr. Erol Fikrig at Yale University School of Medicine.

Small Molecule Therapeutics

L2 has a number of active small molecule programs in: infectious diseases with a particular current emphasis on antibacterials directed at gram-negative organisms such as Pseudomonas aeruginosa; oncology; and immunology / inflammation. We leverage multiple modalities and external collaborations where possible, thus our current programs on inhibitors of macrophage migration inhibitory factor and of BCL6 are aimed at both oncology and inflammatory applications.

Programs are driven by a range of technologies from structure-based approaches, through natural product leads, to high throughput screening. These technologies, together with organic synthesis, X-ray crystallography, and PK/PD studies are conducted by L2 and a long-standing network of specialized contract research organizations.

image of the bacterium Pseudomonas aeruginosa
image of a novel coronavirus SARS-CoV-2


L2 is developing more sensitive and more robust assays of relevance to a number of diseases, including diabetes, Kawasaki disease and emerging tick-borne diseases such as infections by Babesia microti and Borrelia miyamotoi, as well as a novel panel prognostic of toxicity for oncologic treatments employing radiotherapy and check-point inhibitors.

To meet the need the diagnostic challenges of the COVID-19 pandemic, L2 provides and develops highly differentiated assays. L2’s CLIA-certified diagnostic facility performs serology assays for large institutions and corporations. L2 uses this laboratory and consented patient samples to further assess and develop novel assays in this rapidly evolving area.


L2 seeks exceptional scientists who are passionate about making a difference in innovation in global healthcare technology. Contact us.